These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9020950)

  • 1. [Intracellular distribution of bovine serum albumin-conjugated doxorubicin and multidrug resistance].
    Takahashi N; Asakura T; Ohkawa K; Fukuda K; Aoki T
    Gan To Kagaku Ryoho; 1997 Jan; 24(1):87-92. PubMed ID: 9020950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells.
    Asakura T; Takahashi N; Takada K; Inoue T; Ohkawa K
    Anticancer Drugs; 1997 Feb; 8(2):199-203. PubMed ID: 9073316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.
    Ohkawa K; Hatano T; Tsukada Y; Matsuda M
    Br J Cancer; 1993 Feb; 67(2):274-8. PubMed ID: 8431358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma.
    Ohkawa K; Hatano T; Yamada K; Joh K; Takada K; Tsukada Y; Matsuda M
    Cancer Res; 1993 Sep; 53(18):4238-42. PubMed ID: 8364920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells.
    Takahashi N; Asakura T; Ohkawa K
    Anticancer Drugs; 1996 Aug; 7(6):687-96. PubMed ID: 8913438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells.
    Asakura T; Ohkawa K; Takahashi N; Takada K; Inoue T; Yokoyama S
    Br J Cancer; 1997; 76(10):1333-7. PubMed ID: 9374380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristic changes in protein-kinase-C activity and isoforms in ah66 cells during the acquisition of multidrug-resistant phenotype.
    Ohkawa K; Hatano T; Isonishi S; Takada K; Joh K; Matsuda M
    Oncol Rep; 1994 May; 1(3):551-5. PubMed ID: 21607402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of quinine on the multiple drug resistance and intracellular distribution of pirarubicin in LR73 tumor cells: a comparative study with verapamil and S9788 by confocal laser microspectrofluorometry].
    Belhoussine R; Morjani H; Manfait M
    Bull Cancer; 1997 Apr; 84(4):343-9. PubMed ID: 9238156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
    Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
    Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxic effect of the protein-doxorubicin conjugates on the multidrug-resistant human myelogenous leukemia cell line, K562, in vitro.
    Hatano T; Ohkawa K; Matsuda M
    Tumour Biol; 1993; 14(5):288-94. PubMed ID: 8235308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.
    Shen F; Chu S; Bence AK; Bailey B; Xue X; Erickson PA; Montrose MH; Beck WT; Erickson LC
    J Pharmacol Exp Ther; 2008 Jan; 324(1):95-102. PubMed ID: 17947497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spray-dried doxorubicin-albumin microparticulate systems for treatment of multidrug resistant melanomas.
    Jones AK; Bejugam NK; Nettey H; Addo R; D'Souza MJ
    J Drug Target; 2011 Jul; 19(6):427-33. PubMed ID: 20678033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
    Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
    Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiprogestatin drug RU 486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function.
    Lecureur V; Fardel O; Guillouzo A
    FEBS Lett; 1994 Nov; 355(2):187-91. PubMed ID: 7982498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of S9788, cyclosporin A and verapamil on intracellular distribution of THP-doxorubicin in multidrug-resistant K562 tumor cells, as studied by laser confocal microspectrofluorometry.
    Sebille S; Morjani H; Poullain MG; Manfait M
    Anticancer Res; 1994; 14(6A):2389-93. PubMed ID: 7825978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of fatty acids and analogues upon intracellular levels of doxorubicin in cells displaying P-glycoprotein mediated multidrug resistance.
    Abulrob AN; Mason M; Bryce R; Gumbleton M
    J Drug Target; 2000; 8(4):247-56. PubMed ID: 11144235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration.
    Bellamy WT; Dorr RT; Dalton WS; Alberts DS
    Cancer Res; 1988 Nov; 48(22):6360-4. PubMed ID: 3180055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
    Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
    Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.
    Tang J; Zhang L; Gao H; Liu Y; Zhang Q; Ran R; Zhang Z; He Q
    Drug Deliv; 2016 May; 23(4):1130-43. PubMed ID: 25491241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.